<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="07/05/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9796963" creator="Noriko Katsu">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>9796963</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term sem="Other" id="T1" lex="signal_transduction_abnormality">Signal transduction abnormalities</term> in <term sem="Cell_natural" id="T2" lex="T_lymphocyte">T lymphocytes</term> from <term sem="Multicellular_organism_natural" id="T3" lex="patient">patients</term> with advanced <term sem="Other" id="T4" lex="renal_carcinoma">renal carcinoma</term>: clinical relevance and effects of <term sem="Other" id="T5" lex="cytokine_therapy"><term sem="Protein_family_or_group" id="T6" lex="cytokine">cytokine</term> therapy</term>.</sentence>
<event id="E72">
<type class="Regulation" />
<theme idref="T1" />
<cause idref="T6" />
<clue>Signal transduction abnormalities <clueLoc>in T lymphocytes from patients with advanced renal carcinoma</clueLoc>: clinical relevance and <clueType>effects</clueType> <linkCause>of</linkCause> cytokine therapy.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Studies have demonstrated abnormalities of the <term sem="Protein_molecule" id="T7" lex="CD3/T-cell_antigen_receptor"><term sem="Peptide" id="A7">CD3</term>/T-cell antigen receptor</term> (<term sem="Protein_molecule" id="T8" lex="TCR">TCR</term>) and pathways of <term sem="Other" id="T9" lex="signal_transduction">signal transduction</term> in <term sem="Cell_natural" id="T10" lex="T_lymphocyte">T lymphocytes</term> from animals and <term sem="Multicellular_organism_natural" id="T11" lex="patient">patients</term> with <term sem="Other" id="T12" lex="advanced_malignancy">advanced malignancy</term>.</sentence>
<sentence id="S3">Diminished expression of <term sem="Protein_molecule" id="T13" lex="TCRzeta">TCRzeta</term> and <term sem="Protein_molecule" id="T14" lex="p56(lck)">p56(lck)</term> that are associated with the <term sem="Protein_molecule" id="T15" lex="TCR">TCR</term> and reduced nuclear localization of <term sem="Protein_complex" id="T16" lex="RelA_containing_nuclear_factor_kappaB_(NFkappaB)_complex"><term sem="Protein_molecule" id="T17" lex="RelA">RelA</term> containing nuclear factor kappaB (<term sem="Protein_complex" id="T18" lex="NFkappaB">NFkappaB</term>) complexes</term> have been noted.</sentence>
<event id="E4">
<type class="Gene_expression" />
<theme idref="T13" />
<clue>Diminished <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event id="E5">
<type class="Gene_expression" />
<theme idref="T14" />
<clue>Diminished <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event id="E6">
<type class="Binding" />
<theme idref="T13" />
<theme idref="T15" />
<clue>Diminished expression of TCRzeta and p56(lck) that are <clueType>associated</clueType> <linkTheme>with</linkTheme> the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event id="E7">
<type class="Binding" />
<theme idref="T14" />
<theme idref="T15" />
<clue>Diminished expression of TCRzeta and p56(lck) that are <clueType>associated</clueType> <linkTheme>with</linkTheme> the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event id="E8">
<type class="Negative_regulation" />
<theme idref="E4" />
<clue><clueType>Diminished</clueType> expression of TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event id="E9">
<type class="Negative_regulation" />
<theme idref="E5" />
<clue><clueType>Diminished</clueType> expression of TCRzeta and p56(lck) that are associated with the TCR and reduced nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event id="E10">
<type class="Localization" />
<theme idref="T16" />
<clue>Diminished expression of TCRzeta and p56(lck) that are associated with the TCR and reduced <clueLoc>nuclear</clueLoc> <clueType>localization</clueType> <linkTheme>of</linkTheme> RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<event id="E71">
<type class="Negative_regulation" />
<theme idref="E10" />
<clue>Diminished expression of TCRzeta and p56(lck) that are associated with the TCR and <clueType>reduced</clueType> nuclear localization of RelA containing nuclear factor kappaB (NFkappaB) complexes have been noted.</clue>
</event>
<sentence id="S4">These defects have been described in <term sem="Cell_natural" id="T19" lex="T_cell">T cells</term> from <term sem="Multicellular_organism_natural" id="T20" lex="patient">patients</term> with <term sem="Other" id="T21" lex="malignant_melanoma">malignant melanoma</term>, <term sem="Other" id="T22" lex="renal_cell_carcinoma">renal cell carcinoma</term> (<term sem="Other" id="T23" lex="RCC">RCC</term>), <term sem="Other" id="T24" lex="ovarian_cancer">ovarian cancer</term>, and <term sem="Other" id="T25" lex="colorectal_cancer">colorectal cancer</term>.</sentence>
<event id="E11">
<type class="Negative_regulation" />
<theme idref="E8" />
<clue><corefTheme>These</corefTheme> <clueType>defects</clueType> have been described <clueLoc>in T cells</clueLoc> from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer.</clue>
</event>
<event id="E12">
<type class="Negative_regulation" />
<theme idref="E9" />
<clue><corefTheme>These</corefTheme> <clueType>defects</clueType> have been described <clueLoc>in T cells</clueLoc> from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer.</clue>
</event>
<event id="E73">
<type class="Negative_regulation" />
<theme idref="E71" />
<clue><corefTheme>These</corefTheme> <clueType>defects</clueType> have been described <clueLoc>in T cells</clueLoc> from patients with malignant melanoma, renal cell carcinoma (RCC), ovarian cancer, and colorectal cancer.</clue>
</event>
<sentence id="S5">Preliminary observations also indicate possible correlation with clinical variables such as stage in selected instances.</sentence>
<sentence id="S6">To further characterize altered expression of <term sem="Protein_molecule" id="T26" lex="TCRzeta">TCRzeta</term>, <term sem="Protein_molecule" id="T27" lex="p56(lck)">p56(lck)</term>, and impaired activation of <term sem="Protein_complex" id="T28" lex="NFkappaB">NFkappaB</term>, <term sem="Cell_natural" id="T29" lex="T_lymphocyte">T lymphocytes</term> were obtained from 65 <term sem="Multicellular_organism_natural" id="T30" lex="patient">patients</term> with <term sem="Other" id="T31" lex="RCC">RCC</term>, the majority of whom were receiving combination <term sem="Other" id="T32" lex="cytokine_therapy"><term sem="Protein_family_or_group" id="T33" lex="cytokine">cytokine</term> therapy</term> [<term sem="Protein_molecule" id="T34" lex="interleukin_(IL)-2">interleukin (IL)-2</term>, <term sem="Other" id="T35" lex="IFN_alpha-containing_regimen"><term sem="Protein_molecule" id="T36" lex="IFN_alpha">IFN alpha</term>-containing regimens</term>] and 37 control individuals.</sentence>
<event uncertainty="doubtful" id="E13">
<type class="Negative_regulation" />
<theme idref="E15" />
<clue>To further characterize <clueType>altered</clueType> expression of TCRzeta, p56(lck), and impaired activation of NFkappaB, <clueLoc>T lymphocytes</clueLoc> were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
<comment>CAUTION: altered = diminished</comment>
</event>
<event uncertainty="doubtful" id="E14">
<type class="Negative_regulation" />
<theme idref="E16" />
<clue>To further characterize <clueType>altered</clueType> expression of TCRzeta, p56(lck), and impaired activation of NFkappaB, <clueLoc>T lymphocytes</clueLoc> were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
<comment>CAUTION: altered = diminished</comment>
</event>
<event id="E15">
<type class="Gene_expression" />
<theme idref="T26" />
<clue>To further characterize altered <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta, p56(lck), and impaired activation of NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<event id="E16">
<type class="Gene_expression" />
<theme idref="T27" />
<clue>To further characterize altered <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta, p56(lck), and impaired activation of NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<event uncertainty="doubtful" id="E17">
<type class="Negative_regulation" />
<theme idref="E18" />
<clue>To further characterize altered expression of TCRzeta, p56(lck), and <clueType>impaired</clueType> activation of NFkappaB, <clueLoc>T lymphocytes</clueLoc> were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<event id="E18">
<type class="Positive_regulation" />
<theme idref="T28" />
<clue>To further characterize altered expression of TCRzeta, p56(lck), and impaired <clueType>activation</clueType> <linkTheme>of</linkTheme> NFkappaB, T lymphocytes were obtained from 65 patients with RCC, the majority of whom were receiving combination cytokine therapy [interleukin (IL)-2, IFN alpha-containing regimens] and 37 control individuals.</clue>
</event>
<sentence id="S7">In 29 of these <term sem="Multicellular_organism_natural" id="T37" lex="patient">patients</term>, levels of <term sem="Protein_molecule" id="T38" lex="TCRzeta">TCRzeta</term> and <term sem="Protein_molecule" id="T39" lex="p56(lck)">p56(lck)</term> were determined by <term sem="Other" id="T40" lex="Western_blot">Western blots</term> of <term sem="Organic_compound_other" id="T41" lex="T-cell_lysate">T-cell lysates</term> and semiquantitated using <term sem="Other" id="T42" lex="densitometry">densitometry</term>.</sentence>
<event uncertainty="doubtful" id="E19">
<type class="Gene_expression" />
<theme idref="T38" />
<clue>In 29 of these patients, <clueType>levels</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) were determined <clueExperiment>by Western blots of T-cell lysates and semiquantitated using densitometry</clueExperiment>.</clue>
</event>
<event uncertainty="doubtful" id="E20">
<type class="Gene_expression" />
<theme idref="T39" />
<clue>In 29 of these patients, <clueType>levels</clueType> <linkTheme>of</linkTheme> TCRzeta and p56(lck) were determined <clueExperiment>by Western blots of T-cell lysates and semiquantitated using densitometry</clueExperiment>.</clue>
</event>
<sentence id="S8">Relative levels were then correlated with a series of <term sem="Other" id="A3">clinical variables</term> including <term sem="Other" id="T43" lex="response_to_therapy">response to therapy</term>, <term sem="Other" id="T44" lex="performance_status">performance status</term>, survival, <term sem="Other" id="T45" lex="disease_site">disease sites</term>, age, and others.</sentence>
<event uncertainty="doubtful" id="E21">
<type class="Correlation" />
<theme idref="E19" />
<theme idref="A3" />
<clue><corefTheme>Relative levels</corefTheme> were then <clueType>correlated</clueType> <linkTheme>with</linkTheme> a series of clinical variables including response to therapy, performance status, survival, disease sites, age, and others.</clue>
</event>
<event uncertainty="doubtful" id="E22">
<type class="Correlation" />
<theme idref="E20" />
<theme idref="A3" />
<clue><corefTheme>Relative levels</corefTheme> were then <clueType>correlated</clueType> <linkTheme>with</linkTheme> a series of clinical variables including response to therapy, performance status, survival, disease sites, age, and others.</clue>
</event>
<sentence id="S9">In another group of 28 <term sem="Multicellular_organism_natural" id="T46" lex="patient">patients</term> (three individuals from the first group), the frequency of <term sem="Other" id="T47" lex="abnormal_NFkappaB_activation">abnormal <term sem="Protein_complex" id="T48" lex="NFkappaB">NFkappaB</term> activation</term> was studied using electrophoretic mobility shift assays after activation of <term sem="Cell_natural" id="T49" lex="T_cell">T cells</term> with <term sem="Organic_compound_other" id="T50" lex="phorbol_myristate_acetate/ionomycin">phorbol myristate acetate/ionomycin</term> or <term sem="Protein_family_or_group" id="T51" lex="anti-CD3_monoclonal_antibody">anti-CD3 monoclonal antibody</term>.</sentence>
<event uncertainty="doubtful" id="E23">
<type class="Positive_regulation" />
<theme idref="T48" />
<clue>In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB <clueType>activation</clueType> was studied using electrophoretic mobility shift assays after activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
<comment>NER: T47 mod</comment>
</event>
<event uncertainty="doubtful" id="E24">
<type class="Negative_regulation" />
<theme idref="E23" />
<cause idref="E26" />
<clue>In another group of 28 patients (three individuals from the first group), the frequency of <clueType>abnormal</clueType> NFkappaB activation was studied using <clueExperiment>electrophoretic mobility shift assays</clueExperiment> <linkCause>after</linkCause> activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<event uncertainty="doubtful" id="E25">
<type class="Negative_regulation" />
<theme idref="E23" />
<cause idref="E27" />
<clue>In another group of 28 patients (three individuals from the first group), the frequency of <clueType>abnormal</clueType> NFkappaB activation was studied using <clueExperiment>electrophoretic mobility shift assays</clueExperiment> <linkCause>after</linkCause> activation of T cells with phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<event id="E26">
<type class="Physiological_process" />
<theme idref="T49" />
<cause idref="T50" />
<clue>In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB activation was studied using electrophoretic mobility shift assays after <clueType>activation</clueType> <linkTheme>of</linkTheme> T cells <linkCause>with</linkCause> phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<event id="E27">
<type class="Physiological_process" />
<theme idref="T49" />
<cause idref="T51" />
<clue>In another group of 28 patients (three individuals from the first group), the frequency of abnormal NFkappaB activation was studied using electrophoretic mobility shift assays after <clueType>activation</clueType> <linkTheme>of</linkTheme> T cells <linkCause>with</linkCause> phorbol myristate acetate/ionomycin or anti-CD3 monoclonal antibody.</clue>
</event>
<sentence id="S10">Changes in these signaling molecules during <term sem="Other" id="T52" lex="cytokine_treatment"><term sem="Protein_family_or_group" id="T53" lex="cytokine">cytokine</term> treatment</term> were also investigated.</sentence>
<event uncertainty="doubtful" id="E28">
<type class="Positive_regulation" />
<theme idref="T38" />
<cause idref="T52" />
<clue><clueType>Changes</clueType> <linkTheme>in</linkTheme> <corefTheme>these signaling molecules</corefTheme> <linkCause>during</linkCause> cytokine treatment were also investigated.</clue>
</event>
<event uncertainty="doubtful" id="E29">
<type class="Positive_regulation" />
<theme idref="T39" />
<cause idref="T52" />
<clue><clueType>Changes</clueType> <linkTheme>in</linkTheme> <corefTheme>these signaling molecules</corefTheme> <linkCause>during</linkCause> cytokine treatment were also investigated.</clue>
</event>
<sentence id="S11"><term sem="Protein_molecule" id="T54" lex="TCRzeta">TCRzeta</term> and <term sem="Protein_molecule" id="T55" lex="p56(lck)">p56(lck)</term> were detected in the <term sem="Cell_natural" id="T56" lex="peripheral_blood_T_cell">peripheral blood T cells</term> in 27 of 29 <term sem="Multicellular_organism_natural" id="T57" lex="patient">patients</term>, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</sentence>
<event id="E30">
<type class="Gene_expression" />
<theme idref="T54" />
<clue>TCRzeta and p56(lck) were <clueType>detected</clueType> <clueLoc>in the peripheral blood T cells</clueLoc> in 27 of 29 patients, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<event id="E31">
<type class="Gene_expression" />
<theme idref="T55" />
<clue>TCRzeta and p56(lck) were <clueType>detected</clueType> <clueLoc>in the peripheral blood T cells</clueLoc> in 27 of 29 patients, and overall, reduced levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<event id="E32">
<type class="Negative_regulation" />
<theme idref="E30" />
<clue>TCRzeta and p56(lck) were detected in the peripheral blood T cells in 27 of 29 patients, and overall, <clueType>reduced</clueType> levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<event id="E33">
<type class="Negative_regulation" />
<theme idref="E30" />
<clue>TCRzeta and p56(lck) were detected in the peripheral blood T cells in 27 of 29 patients, and overall, <clueType>reduced</clueType> levels were noted visually in 12 of 29 (41%) and 13 of 29 (45%) individuals, respectively.</clue>
</event>
<sentence id="S12">When levels were semiquantitated using <term sem="Other" id="T58" lex="densitometry">densitometry</term>, significant decreases of <term sem="Protein_molecule" id="T59" lex="TCRzeta">TCRzeta</term> (P = 0.029) and <term sem="Protein_molecule" id="T60" lex="p56(lck)">p56(lck)</term> (P = 0.029) but not <term sem="Protein_molecule" id="T61" lex="CD3epsilon">CD3epsilon</term> (P = 0.131), compared with control levels, were found.</sentence>
<event id="E35">
<type class="Negative_regulation" />
<theme idref="T59" />
<clue>When levels were <clueExperiment>semiquantitated using densitometry</clueExperiment>, significant <clueType>decreases</clueType> <linkTheme>of</linkTheme> TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but not CD3epsilon (P = 0.131), compared with control levels, were found.</clue>
</event>
<event id="E36">
<type class="Negative_regulation" />
<theme idref="T60" />
<clue>When levels were <clueExperiment>semiquantitated using densitometry</clueExperiment>, significant <clueType>decreases</clueType> <linkTheme>of</linkTheme> TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but not CD3epsilon (P = 0.131), compared with control levels, were found.</clue>
</event>
<event assertion="non-exist" id="E37">
<type class="Negative_regulation" />
<theme idref="T61" />
<clue>When levels were <clueExperiment>semiquantitated using densitometry</clueExperiment>, significant <clueType>decreases</clueType> <linkTheme>of</linkTheme> TCRzeta (P = 0.029) and p56(lck) (P = 0.029) but not CD3epsilon (P = 0.131), compared with control levels, were found.</clue>
</event>
<sentence id="S13">In <term sem="Multicellular_organism_natural" id="T62" lex="patient">patients</term> treated with <term sem="Protein_molecule" id="A5">IL-2</term>/<term sem="Other" id="T63" lex="IFN_alpha-based_therapy"><term sem="Protein_molecule" id="T64" lex="IFN_alpha">IFN alpha</term>-based therapy</term>, relative levels of <term sem="Protein_molecule" id="T65" lex="TCRzeta">TCRzeta</term> increased significantly (P = 0.002) on day 15 of cycle one compared with the baseline.</sentence>
<event id="E38">
<type class="Positive_regulation" />
<theme idref="T65" />
<cause idref="A5" />
<cause idref="T64" />
<clue>In patients treated <linkCause>with</linkCause> IL-2/IFN alpha-based therapy, relative levels of TCRzeta <clueType>increased</clueType> significantly (P = 0.002) <clueTime>on day 15 of cycle one</clueTime> compared with the baseline.</clue>
</event>
<sentence id="S14">Correlations of <term sem="Protein_molecule" id="T66" lex="TCRzeta">TCRzeta</term> or <term sem="Protein_molecule" id="T67" lex="p56(lck)">p56(lck)</term> levels with response or disease variables, except for lower <term sem="Other" id="T68" lex="TCRzeta_level"><term sem="Protein_molecule" id="T69" lex="TCRzeta">TCRzeta</term> levels</term> (P &lt; 0.001) in the presence of <term sem="Tissue_natural" id="T70" lex="bone_metastasis">bone metastases</term>, were not found.</sentence>
<event id="E39">
<type class="Negative_regulation" />
<theme idref="T69" />
<cause idref="T70" />
<clue>Correlations of TCRzeta or p56(lck) levels with response or disease variables, except for <clueType>lower</clueType> TCRzeta <clueType>levels</clueType> (P &lt; 0.001) <linkCause>in the presence of</linkCause> bone metastases, were not found.</clue>
</event>
<sentence id="S15"><term sem="Other" id="T71" lex="abnormal_NFkappaB_activation">Abnormal <term sem="Protein_complex" id="T72" lex="NFkappaB">NFkappaB</term> activation</term> after stimulation with <term sem="Organic_compound_other" id="T73" lex="phorbol_myristate_acetate/ionomycin">phorbol myristate acetate/ionomycin</term> and/or <term sem="Protein_family_or_group" id="T74" lex="anti-CD3_monoclonal_antibody">anti-CD3 monoclonal antibody</term> was found in 59% of <term sem="Multicellular_organism_natural" id="T75" lex="patient">patients</term> (17 of 28) and was not accounted for by the advanced age of the study cohort.</sentence>
<event id="E40">
<type class="Positive_regulation" />
<theme idref="T72" />
<cause idref="E43" />
<clue>Abnormal NFkappaB <clueType>activation</clueType> <linkCause>after</linkCause> stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
</event>
<event id="E1">
<type class="Positive_regulation" />
<theme idref="T72" />
<cause idref="E44" />
<clue>Abnormal NFkappaB <clueType>activation</clueType> <linkCause>after</linkCause> stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
</event>
<event id="E41">
<type class="Negative_regulation" />
<theme idref="E40" />
<clue><clueType>Abnormal</clueType> NFkappaB activation after stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>CAUTION, abnormal</comment>
</event>
<event id="E42">
<type class="Negative_regulation" />
<theme idref="E1" />
<cause idref="E43" />
<clue><clueType>Abnormal</clueType> NFkappaB activation after stimulation with phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>CAUTION, abnormal</comment>
</event>
<event id="E43">
<type class="Positive_regulation" />
<cause idref="T73" />
<clue>Abnormal NFkappaB activation after <clueType>stimulation</clueType> <linkCause>with</linkCause> phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>NO THEME</comment>
</event>
<event id="E44">
<type class="Positive_regulation" />
<cause idref="T74" />
<clue>Abnormal NFkappaB activation after <clueType>stimulation</clueType> <linkCause>with</linkCause> phorbol myristate acetate/ionomycin and/or anti-CD3 monoclonal antibody was found in 59% of patients (17 of 28) and was not accounted for by the advanced age of the study cohort.</clue>
<comment>NO THEME</comment>
</event>
<sentence id="S16">Activation of <term sem="Protein_complex" id="T76" lex="NFkappaB">NFkappaB</term> in <term sem="Cell_natural" id="T77" lex="peripheral_blood_T_cell">peripheral blood T cells</term> was inducible during <term sem="Other" id="T78" lex="cytokine_therapy"><term sem="Protein_family_or_group" id="T79" lex="cytokine">cytokine</term> therapy</term> in four of six individuals who displayed impaired <term sem="Protein_complex" id="T80" lex="NFkappaB">NFkappaB</term> activity prior to therapy.</sentence>
<event id="E45">
<type class="Positive_regulation" />
<theme idref="T76" />
<clue><clueType>Activation</clueType> <linkTheme>of</linkTheme> NFkappaB <clueLoc>in peripheral blood T cells</clueLoc> was inducible during cytokine therapy in four of six individuals who displayed impaired NFkappaB activity prior to therapy.</clue>
</event>
<event id="E46">
<type class="Positive_regulation" />
<theme idref="E45" />
<cause idref="T78" />
<clue>Activation of NFkappaB in peripheral blood T cells was <clueType>inducible</clueType> <linkCause>during</linkCause> cytokine therapy in four of six individuals who displayed impaired NFkappaB activity prior to therapy.</clue>
</event>
<sentence id="S17">Moreover, impaired activation of <term sem="Protein_complex" id="T81" lex="NFkappaB">NFkappaB</term> does not appear linked to a reduction of <term sem="Other" id="T82" lex="TCRzeta_expression"><term sem="Protein_molecule" id="T83" lex="TCRzeta">TCRzeta</term> expression</term>, because in five <term sem="Multicellular_organism_natural" id="T84" lex="patient">patients</term>, <term sem="Other" id="T85" lex="normal_TCRzeta_level">normal <term sem="Protein_molecule" id="T86" lex="TCRzeta">TCRzeta</term> levels</term> were present although <term sem="Protein_molecule" id="T87" lex="kappaB">kappaB</term> binding was not inducible.</sentence>
<event id="E47">
<type class="Positive_regulation" />
<theme idref="T81" />
<clue>Moreover, impaired <clueType>activation</clueType> <linkTheme>of</linkTheme> NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event id="E48">
<type class="Negative_regulation" />
<theme idref="E47" />
<clue>Moreover, <clueType>impaired</clueType> activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event assertion="non-exist" uncertainty="probable" id="E49">
<type class="Correlation" />
<theme idref="E48" />
<theme idref="E51" />
<clue>Moreover, impaired activation of NFkappaB does not appear <clueType>linked</clueType> to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event id="E50">
<type class="Gene_expression" />
<theme idref="T83" />
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta <clueType>expression</clueType>, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event id="E51">
<type class="Negative_regulation" />
<theme idref="E50" />
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a <clueType>reduction</clueType> <linkTheme>of</linkTheme> TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not inducible.</clue>
</event>
<event id="E52">
<type class="Binding" />
<theme idref="T87" />
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB <clueType>binding</clueType> was not inducible.</clue>
</event>
<event assertion="non-exist" uncertainty="probable" id="E53">
<type class="Positive_regulation" />
<theme idref="E52" />
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were present although kappaB binding was not <clueType>inducible</clueType>.</clue>
</event>
<event assertion="non-exist" id="E54">
<type class="Correlation" />
<theme idref="T85" />
<theme idref="E53" />
<clue>Moreover, impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression, because in five patients, normal TCRzeta levels were <clueType>present</clueType> <linkTheme>although</linkTheme> kappaB binding was not inducible.</clue>
</event>
<sentence id="S18">In the majority of <term sem="Multicellular_organism_natural" id="T88" lex="patient">patients</term> with advanced <term sem="Other" id="T89" lex="RCC">RCC</term>, <term sem="Cell_natural" id="T90" lex="peripheral_blood_T_cell">peripheral blood T cells</term> express <term sem="Protein_molecule" id="T91" lex="TCRzeta">TCRzeta</term> and <term sem="Protein_molecule" id="T92" lex="p56(lck)">p56(lck)</term>, and in a subset, reduced levels of these <term sem="Protein_family_or_group" id="T93" lex="TCRzeta_associated_molecule"><term sem="Protein_molecule" id="T94" lex="TCRzeta">TCRzeta</term> associated molecules</term> are seen that may increase during <term sem="Other" id="T95" lex="cytokine-based_therapy"><term sem="Protein_family_or_group" id="T96" lex="cytokine">cytokine</term>-based therapy</term>.</sentence>
<event id="E55">
<type class="Gene_expression" />
<theme idref="T91" />
<clue>In the majority of patients with advanced RCC, <clueLoc>peripheral blood T cells</clueLoc> <clueType>express</clueType> TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may increase during cytokine-based therapy.</clue>
</event>
<event id="E56">
<type class="Gene_expression" />
<theme idref="T92" />
<clue>In the majority of patients with advanced RCC, <clueLoc>peripheral blood T cells</clueLoc> <clueType>express</clueType> TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may increase during cytokine-based therapy.</clue>
</event>
<event id="E57">
<type class="Negative_regulation" />
<theme idref="T91" />
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and <clueLoc>in a subset</clueLoc>, <clueType>reduced levels</clueType> <linkTheme>of</linkTheme> <corefTheme>these TCRzeta associated molecules</corefTheme> are seen that may increase during cytokine-based therapy.</clue>
</event>
<event id="E58">
<type class="Negative_regulation" />
<theme idref="T92" />
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and <clueLoc>in a subset</clueLoc>, <clueType>reduced levels</clueType> <linkTheme>of</linkTheme> <corefTheme>these TCRzeta associated molecules</corefTheme> are seen that may increase during cytokine-based therapy.</clue>
</event>
<event id="E59">
<type class="Positive_regulation" />
<theme idref="E57" />
<cause idref="T95" />
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may <clueType>increase</clueType> <linkCause>during</linkCause> cytokine-based therapy.</clue>
</event>
<event id="E60">
<type class="Positive_regulation" />
<theme idref="E58" />
<cause idref="T95" />
<clue>In the majority of patients with advanced RCC, peripheral blood T cells express TCRzeta and p56(lck), and in a subset, reduced levels of these TCRzeta associated molecules are seen that may <clueType>increase</clueType> <linkCause>during</linkCause> cytokine-based therapy.</clue>
</event>
<sentence id="S19">Abnormal activation of <term sem="Protein_complex" id="T97" lex="NFkappaB">NFkappaB</term> is also present in &gt;50% of <term sem="Multicellular_organism_natural" id="T98" lex="patient">patients</term> and may also revert to normal during <cons sem="(/ Other Other)" id="C1" lex="(/ IL-2-based_treatment IFN_alpha-based_treatment)"><frag id="F1"><term sem="Protein_molecule" id="A6">IL-2</term></frag>/<frag id="F2"><term sem="Protein_molecule" id="T100" lex="IFN_alpha">IFN alpha</term></frag><frag id="F3">-based treatment</frag></cons>.</sentence>
<event id="E61">
<type class="Positive_regulation" />
<theme idref="T97" />
<clue>Abnormal <clueType>activation</clueType> <linkTheme>of</linkTheme> NFkappaB is also present in &gt;50% of patients and may also revert to normal during IL-2/IFN alpha-based treatment.</clue>
</event>
<event id="E62">
<type class="Negative_regulation" />
<theme idref="E61" />
<clue><clueType>Abnormal</clueType> activation of NFkappaB is also present in &gt;50% of patients and may also revert to normal during IL-2/IFN alpha-based treatment.</clue>
<comment>CAUTION, abnormal</comment>
</event>
<event id="E63">
<type class="Negative_regulation" />
<theme idref="E62" />
<cause idref="A6" />
<cause idref="T100" />
<clue>Abnormal activation of NFkappaB is also present in &gt;50% of patients and may also <clueType>revert to normal</clueType> <linkCause>during</linkCause> IL-2/IFN alpha-based treatment.</clue>
</event>
<sentence id="S20">This alteration in <term sem="Other" id="T101" lex="NFkappaB_activation"><term sem="Protein_complex" id="T102" lex="NFkappaB">NFkappaB</term> activation</term> occurred in the presence of normal expression of <term sem="DNA_family_or_group" id="T103" lex="TCRzeta-associated_signaling_element"><term sem="Protein_molecule" id="T104" lex="TCRzeta">TCRzeta</term>-associated signaling elements</term>.</sentence>
<event id="E64">
<type class="Positive_regulation" />
<theme idref="E65" />
<cause idref="E66" />
<clue>This <clueType>alteration</clueType> <linkTheme>in</linkTheme> NFkappaB activation occurred <linkCause>in the presence of</linkCause> normal expression of TCRzeta-associated signaling elements.</clue>
</event>
<event id="E65">
<type class="Positive_regulation" />
<theme idref="T102" />
<clue>This alteration in NFkappaB <clueType>activation</clueType> occurred in the presence of normal expression of TCRzeta-associated signaling elements.</clue>
</event>
<event id="E66">
<type class="Gene_expression" />
<theme idref="T103" />
<clue>This alteration in NFkappaB activation occurred in the presence of normal <clueType>expression</clueType> <linkTheme>of</linkTheme> TCRzeta-associated signaling elements.</clue>
</event>
<sentence id="S21">The clinical significance of these findings remains unclear.</sentence>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
